<DOC>
	<DOCNO>NCT01501981</DOCNO>
	<brief_summary>In pilot , investigator-initiated multi-centre , multinational , observational study investigator would like examine impact therapy optimization level biomarkers patient acute decompensated decompensated chronic heart failure . The primary objective determine best time point measure biomarker level therapy optimization patient decompensation predict clinical outcome mortality , hospitalisation , quality life . Secondary objective : 1 . To evaluate impact guideline-recommended medication biomarker level follow recompensation . 2 . To evaluate whether trajectory relevant biomarkers ( MR-proANP , MR-proADM ) relevance guide medical therapy follow decompensation . 3 . To evaluate whether degree biomarker change ( e.g . slow versus rapid change ) relevance regard hemodynamic stability cardiovascular event hospitalisation . 4 . To evaluate whether trajectory relevant biomarkers ( copeptin , CT-pro-ET1 ) relevance guide medical therapy follow decompensation .</brief_summary>
	<brief_title>Impact Therapy Optimization Level Biomarkers Patients With Decompensated Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Male female patient ≥ 18 year . 2 . Hospitalized ADHF decompensated chronic heart failure . Patients develop ADHF hospitalize another reason eligible . 3 . The underlying primary etiology decompensation cardiac rather pulmonary disease . For study , follow must observable time screening : Dyspnea rest ( sit supine ) minimal exertion ( talk , eat , etc . ) NYHA III/IV ; Pulmonary congestion physical examination chest xray ; 4 . Able begin study within 24 hour presentation hospital , include time spent emergency department . 5 . Be adequately informed nature risk study give write informed consent prior study start . 1 . Acute suspect acute myocardial infarction ( AMI ) troponin level &gt; 3x upper limit normal . institution 's local laboratory . 2 . Cardiogenic shock . 3 . Temperature &gt; 38°C ( oral equivalent ) , sepsis active infection require IV antimicrobial treatment . 4 . ADHF due significant arrhythmia ( ventricular tachycardia , bradyarrhythmias ventricular rate &lt; 45 bpm atrial fibrillation/flutter ventricular response &gt; 150 bpm ) . 5 . Current planned ultrafiltration , hemofiltration , dialysis . 6 . Significant pulmonary disease ( history oral daily steroid dependency , history CO2 retention need intubation acute exacerbation , currently receive IV steroid ) , thoracic cage injury compromise breathe . 7 . Any organ transplant recipient patient currently list admit transplantation . 8 . Acute myocarditis hypertrophic obstructive , restrictive , constrictive cardiomyopathy ( include restrictive mitral valve fill pattern ) . 9 . Women pregnant breastfeeding . 10 . Malignant disease life expectancy less two year . 11 . Autoimmune disease . 12 . Any condition treatment condition , opinion investigator , could interfere conduct study , would unacceptably increase risk patient 's participation study . This may include , limited , alcoholism , drug dependency abuse , severe mental disorder , epilepsy , unexplained episode syncope .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>heart failure</keyword>
	<keyword>MR-proANP</keyword>
	<keyword>MR-proADM</keyword>
	<keyword>decompensation</keyword>
	<keyword>Copeptin</keyword>
	<keyword>CT-proET1</keyword>
	<keyword>NT-proBNP</keyword>
</DOC>